Oura asks investors to value data over hardware in Nasdaq IPO

Oura’s IPO filing is built around a simple proposition: the company wants investors to value it as a health-data platform rather than a wearable brand.

The financials support much of that argument. Revenue rose 74 percent to $1.21 billion in the first nine months of fiscal 2026, membership revenue more than doubled, and the company reported its first sustained period of GAAP profitability. Yet the prospectus arrives with an unresolved challenge at the center of that investment case. An active class action is questioning the accuracy of some of the biometric data on which Oura’s health and AI ambitions rest.

That matters because the filing spends far less time selling rings than it does selling data. Oura’s valuation case is built on growing subscriptions, long-term member retention and a biometric dataset the company says now spans nearly 42 billion hours. The question for investors is not whether Oura can sell more devices, but whether the health insights derived from those devices prove durable enough to justify a technology valuation rather than a consumer-electronics multiple.

The filing, lodged with the U.S. Securities and Exchange Commission, followed a confidential submission in May.

Profitable for the first time, and a record loss too

The filing, lodged with the U.S. Securities and Exchange Commission, followed a confidential submission in May, according to earlier reporting from TechCrunch. It corroborated reporting from Reuters and Quartz on the headline growth figures and added detail those reports did not carry.

The net income and net loss figures aren’t contradictory, they’re measuring different things. The $924.3 million loss comes from a one-time accounting entry related to Oura’s preferred shares ahead of the IPO. It’s a paper adjustment, not money the company actually lost running the business. Set that aside, and Oura’s underlying business was solidly profitable, its strongest period yet, though it has posted small positive net income before. 

Oura’s fastest-growing customer isn’t the first-time wearable buyer, it’s women

Subscriptions, not hardware, are the core investment thesis. Oura estimates its addressable market at more than $90 billion once fitness tracking, coaching, digital therapeutics and connected biosensors are counted alongside hardware, against roughly 2 percent of global wearable shipments today.

A third of new members report Oura as their first wearable device, which the company uses to argue it is expanding the category rather than just taking share from Garmin, Fitbit or general-purpose smartwatches.

Nearly three-quarters of members are women, a base Oura says has grown at a faster rate than its male member base since fiscal 2024, concentrated around cycle tracking, conception and, increasingly, pregnancy and menopause support delivered through a custom large-language model built specifically for women’s health.

Oura’s real product is a “data moat” that gets harder to copy over time

That data asset, nearly 42 billion hours of longitudinal biometric information by Oura’s count, is what the filing positions as the durable advantage: hardware recovers acquisition cost, membership compounds engagement, and the resulting dataset trains proprietary health models that get harder to replicate the longer members stay.

Clinical integrations with partners including Eli Lilly’s LillyDirect platform, ResMed and Dexcom’s Stelo glucose sensor extend that data relationship from wellness tracking toward care pathways, employer benefits and health-plan integrations, the direction Oura says its long-term opportunity actually lies.

The lawsuit that could undercut Oura’s whole pitch

The principal risk highlighted by the filing is whether Oura’s claims around data accuracy can withstand legal and regulatory scrutiny. Oura’s own risk factors flag “litigation and regulatory proceedings relating to claims we make about that accuracy” as a named risk to the business, alongside a pending consumer class action alleging the ring’s sleep-stage estimates are little more reliable than chance.

Oura has disputed the claims. The filing states research-grade accuracy of roughly 96 percent for sleep and ovulation tracking, figures drawn from the company’s own studies rather than independent replication, which is the exact category of claim now being tested in court.

The SEC filing tracks with what SGIE has observed developing over time: a shift to models where subscription-and-data economics, not unit sales, determine how premium wearables get valued, pressuring hardware-first competitors to build or partner into a comparable software and clinical layer.

FitnessBrands, technology and the new formats of sport

From training sportswear and wearables to connected home equipment and hybrid race formats,SGI Europe covers fitness through the lens of brands, retailers, and the product strategies that define the category.

Explore Fitness →